1. Home
  2. DMAC vs HYI Comparison

DMAC vs HYI Comparison

Compare DMAC & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • HYI
  • Stock Information
  • Founded
  • DMAC 2000
  • HYI 2010
  • Country
  • DMAC United States
  • HYI United States
  • Employees
  • DMAC N/A
  • HYI N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • HYI Investment Managers
  • Sector
  • DMAC Health Care
  • HYI Finance
  • Exchange
  • DMAC Nasdaq
  • HYI Nasdaq
  • Market Cap
  • DMAC 310.1M
  • HYI 270.9M
  • IPO Year
  • DMAC N/A
  • HYI N/A
  • Fundamental
  • Price
  • DMAC $5.98
  • HYI $11.90
  • Analyst Decision
  • DMAC Strong Buy
  • HYI
  • Analyst Count
  • DMAC 3
  • HYI 0
  • Target Price
  • DMAC $12.33
  • HYI N/A
  • AVG Volume (30 Days)
  • DMAC 314.0K
  • HYI 50.6K
  • Earning Date
  • DMAC 08-12-2025
  • HYI 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • HYI 9.59%
  • EPS Growth
  • DMAC N/A
  • HYI N/A
  • EPS
  • DMAC N/A
  • HYI N/A
  • Revenue
  • DMAC N/A
  • HYI N/A
  • Revenue This Year
  • DMAC N/A
  • HYI N/A
  • Revenue Next Year
  • DMAC N/A
  • HYI N/A
  • P/E Ratio
  • DMAC N/A
  • HYI N/A
  • Revenue Growth
  • DMAC N/A
  • HYI N/A
  • 52 Week Low
  • DMAC $3.19
  • HYI $10.99
  • 52 Week High
  • DMAC $6.82
  • HYI $12.24
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 65.09
  • HYI 45.49
  • Support Level
  • DMAC $5.90
  • HYI $11.83
  • Resistance Level
  • DMAC $6.18
  • HYI $11.98
  • Average True Range (ATR)
  • DMAC 0.39
  • HYI 0.09
  • MACD
  • DMAC 0.02
  • HYI -0.01
  • Stochastic Oscillator
  • DMAC 79.10
  • HYI 29.17

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

Share on Social Networks: